Google has announced that it will be lowering the search ranking of sites that it doesn't consider to me "mobile friendly." Unfortunately, that includes Blood Sugar 101 and its Low Carb sister site.
So we have been changing the layout of the site to make it possible to easily convert it to mobile format. The content has not changed, other than a few editorial tweaks. The process will take a few days to complete.
We hope you like the new layout!
Tuesday, April 21, 2015
Friday, April 17, 2015
FDA to add warning to Onglyza label warning of greatly increased risk of heart failure
Page Changed: DPP-4 Inhibitors: Januvia, Onglyza, Trajenta, Combiglyze, Janumet, and Jentadueto
Added text:
In April of 2015, the data was made public that the SAVOR study showed that people taking Onglyza were 27% more likely to be hospitalized for heart failure. As a result, the FDA decided to add warning information about heart failure to the Onglyza label. (Details HERE.) However, few doctors keep up with changes to the labels of the drugs they prescribe. And as the FDA still considers this to be an acceptable drug, it will continue to be prescribed. This kind of FDA response is in line with its policy of putting the interests drug companies above those of drug users.
Added text:
In April of 2015, the data was made public that the SAVOR study showed that people taking Onglyza were 27% more likely to be hospitalized for heart failure. As a result, the FDA decided to add warning information about heart failure to the Onglyza label. (Details HERE.) However, few doctors keep up with changes to the labels of the drugs they prescribe. And as the FDA still considers this to be an acceptable drug, it will continue to be prescribed. This kind of FDA response is in line with its policy of putting the interests drug companies above those of drug users.
Friday, April 3, 2015
Several New GLP-1 Agonists Added to the Web Page. All Are Potentially Cancer-provoking.
Page Changed: GLP-1 Agonists: Byetta, Lyxumia, Bydureon, Victoza, Trulicity and Tanzeum
Text Added:
Byetta, Lyxumia, Bydureon, Victoza, Trulicity and Tanzeum
These drugs are all members of the incretin drug family. Byetta (exenatide) is injected several times a day, Victoza (liraglutide) and Lyxumia (lixisenatide) once a day. Saxenda is the same drug as Victoza, but it has been approved for people without diabetes who need to achieve weight loss. Bydureon is a long lasting version of exenatide. It, Trulicity, (dulaglutide) and Tanzeum (albiglutide) are injected once and last a full week.
Subscribe to:
Posts (Atom)
